"We are very excited about this acquisition," said Norman Schwartz, Bio-Rad vice president and Life Science Group manager. "It is a natural extension of our DNA- and proteome-based product lines, augmenting our existing gene transfer, amplification and imaging products. We expect microarray technologies to become a standard method used in molecular biology laboratories, and this gives us an excellent entree into this fast growing market."